In January 2016, two key players Sanofi and Mankind entered into a joint venture to develop an inhalable insulin
drug named Afreeza.
The news is an important reminder that MannKind's inhalation drug delivery platforms offer potentially much more value than just Afrezza inhalable insulin
, the analyst contends.
was approved for therapeutic use in the US in 2006, but its sales eventually flopped and was pulled out of shelves, despite positive reviews from users.
For instance, in February 2015, Sanofi and Mankind Corporation (U.S.) collaborated to launch Afrezza (insulin human) Inhalation Powder, inhalable insulin
. This launch enabled the company to strengthen its product portfolio in nasal drug delivery.
Separately, Riccardo Perfetti, senior medical officer for diabetes at Sanofi, briefed analysts on launch plans for inhalable insulin
I am reminded of this because the FDA recently approved MannKind's inhalable insulin
One such example is inhalable insulin
. Although the first commercial trials from around 2006 initially failed, a comeback may be imminent: The U.S.
So might something that was in the news last month: the decision by an FDA advisory panel to approve Afrezza, an inhalable insulin
produced by MannKind Corporation, for clinical trials.
He shows managers and leaders tools to create a strategy to build and shape innovation ecosystems and illustrates those that failed and succeeded, such as Nokia's 3G handset that failed to profit because partners in its ecosystem did not complete their innovations in time; Pfizer's inhalable insulin
, which failed when endocrinologists wouldn't allow the requirement of lung function testing; Michelin's tires designed to run for 125 miles after a blowout, impacted by a failure in understanding the way in which service centers would adopt the solution; and successes like Amazon, Hasbro, and Apple.
But history is littered with great products that never quite made it, from electric cars to inhalable insulin
to any e-reader that came out before the Kindle.
(New York, NY) said that the United States District Court for the Southern District of New York has denied a motion for a preliminary injunction that would have blocked further sales of its inhalable insulin
medication, Exubera, in the United States.